Ocusun Ophthalmic Pharmaceutical

Ocusun is a clinical-stage biopharmaceutical company based in China that specializes in the development and commercialization of innovative ophthalmic therapies. The company's lead candidate, OC-101, is a multi-target tyrosine kinase inhibitor (TKI) designed for the treatment of neovascular age-related macular degeneration and other retinal vascular diseases. Ocusun focuses on addressing unmet medical needs in ophthalmology through advanced drug delivery systems and novel small molecule formulations. Their pipeline includes treatments for prevalent eye conditions such as glaucoma and dry eye syndrome, aiming to provide more effective and convenient options for patients globally.